Indivior settles addiction treatment case with Mylan for undisclosed terms

Sept 25 (Reuters) - Indivior's U.S. subsidiary, together with Monosol Rx, has settled a patent dispute with U.S. drugmaker Mylan related to generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of the Indivior's revenue.